Premium
Pharmacokinetics and Renal Effects of Cidofovir with a Reduced Dose of Probenecid in HIV‐Infected Patients with Cytomegalovirus Retinitis
Author(s) -
Wolf Daniel L.,
Rodríguez Carlos A.,
Mucci Massimiliano,
Ingrosso Antonella,
Duncan Barbara A.,
Nickens Dana J.
Publication year - 2003
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270002239705
Subject(s) - probenecid , cidofovir , pharmacokinetics , medicine , regimen , pharmacology , renal function , human cytomegalovirus , urology , virology , virus
To reduce possible nephrotoxicity, intravenous prehydration with normal saline and administration of probenecid must be used with each infusing of the antiviral cidofovir. The recommended standard‐dose probenecid (SDP) regimen is 2 g at 3 hours before cidofovir, then 1 g at 2 and 8 hours after cidofovir (total 4 g). A new regimen of reduced‐dose probenecid (RDP), 2 g at 1 hour before cidofovir without additional probenecid administrations after infusion (total 2 g), was compared with SDP using a randomized, open‐label, parallel design. A single dose of cidofovir (5 mg/kg) was given as a 1‐hour infusion after saline prehydration to 24 HIV‐infected patients (11 males, 13 females) with cytomegalovirus retinitis and good renal function. Blood was sampled for 48 hours and urine for 24 hours after the start of the cidofovir infusion. Cidofovir pharmacokinetics did not differ significantly between groups. Average key pharmacokinetic parameters (C max , t max , Λ z , AUC 0‐∞ , V ss , CL, CL R , fe, ER) for RDP differed by less than 17% from SDP and were consistent with previously reported SDP data. Renal function parameters, other safety endpoints, and adverse events were similar between the groups. Therefore, the reduced‐dose regimen of probenecid provided renal protection after a single dose of cidofovir and did not alter the pharmacokinetics of cidofovir in patients with moderately good renal function. Although the overall pharmacokinetic results do not show a significant difference in cidofovir exposure with the new probenecid regimen, the main issue of safety of the new dose regimen, both relating to renal toxicity and probenecid‐related adverse events, is not adequately addressed in a small study.